Sabine Brookman-May, VP Global Head of Clinical Development at Curium Pharma, shared a post on LinkedIn:
“Very excited to share that today I am starting a new chapter as VP Global Head of Clinical Development at Curium Pharma.
After an intense and rewarding time at Aura Biosciences, it felt like the right moment to shift gears again – and to reconnect to prostate cancer as an area that has been close to me for many years during my work at Johnson & Johnson Innovative Medicine and to expand my expertise to one of the most transformative areas in oncology: Radioligand Therapy and precision imaging.
At Curium, I’ll be leading the global clinical development of the radiopharmaceutical portfolio working across clinical operations, medical, regulatory, and strategy. What excites me most is the opportunity to help shape the future of precision diagnostics and therapies in prostate cancer, while also expanding into potential new indications where radiopharmaceuticals can make a real difference, defining smarter trial designs, improved patient selection, and tighter integration of diagnostics and therapeutics.
Looking forward to building, challenging assumptions, and pushing the field forward – together with exceptional teams across the organization and external collaborators and experts in the field.”
More posts featuring Sabine Brookman-May.